article thumbnail

Novartis halts recruitment of Kisqali trials as it adjusts production methods

Fierce Pharma

In response to recent FDA guidelines which limit the nitrosamine content of drugs, Novartis has paused the enrollment of early breast cancer (eBC) patients in clinical trials of its blockbuster Kis | In response to recent FDA guidelines which limit the nitrosamine content of drugs, Novartis has paused the enrollment of early breast cancer (eBC) patients (..)

article thumbnail

Promising Remote Patient Monitoring solution, Polso, Achieves 1st FDA Clearance

Legacy MEDSearch

took a step towards its vision of transforming chronic care management with Polso , the company’s Remote Patient Monitoring (RPM) solution, achieving 510(k) clearance from the U.S. Food and Drug Administration (FDA). “FDA clearance is an important validation of our technology. ChroniSense Medical Ltd.

FDA 97
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Has Trump damaged the FDA beyond repair?

World of DTC Marketing

It all comes down to trust in the FDA, which has been damaged severely by an anti-science failed leader. ” On Friday, the Washington Post posted, on their front page, that a member of the Trump Administration told the FDA’s head to approve the vaccine that day or else he would be looking for a new job.

FDA 271
article thumbnail

Aerin Medical Receives FDA Clearance of Next-Generation RhinAer® Stylus for Treatment of Patients with Chronic Rhinitis

Legacy MEDSearch

Food and Drug Administration (FDA) 510(k) clearance and launch of a next-generation RhinAer® stylus. The new RhinAer is designed to provide physicians with improved visualization, easier access and tissue apposition, especially in patients with narrow nasal airways. Aerin Medical Inc.,

Medical 98
article thumbnail

FDA Approves LimFlow System in Patients With Chronic Limb-Threatening Ischemia and No Suitable Endovascular or Surgical Revascularization Options

Legacy MEDSearch

Food and Drug Administration (FDA) has approved the LimFlow System to help people with CLTI who have no other suitable endovascular or surgical treatment options and are facing major amputation. 4 The LimFlow System is the first and only FDA-approved device for TADV and previously received Breakthrough Device Designation from the FDA. “At

FDA 52
article thumbnail

Clinical trial DTC? It may not be right for your drug candidate

World of DTC Marketing

DTC may or may not work for clinical trial enrollment it really depends on the condition and risk as judged by the patient. More than 40 million patients are needed to meet the demand of currently enrolling trials. More than 18,000 clinical trials are actively recruiting patients in the U.S. According to antidote.com.

article thumbnail

The Future of RWE in Clinical Trial Design and Recruitment

Clarify Health

Less than four percent of Americans participate in clinical studies; 30 percent of patients drop out; and 80 percent of studies do not meet enrollment deadlines. Dr. Rizk provided an example of how we’re getting better at meeting patients where they are. Below are highlights and key takeaways from the panel.